VNT has had a brutal week. The stock shed 14.4% in five sessions to close at $30.09, a one-month loss of nearly 15%, after Q1 results landed badly on May 7. Short sellers have moved decisively in the same direction as the tape.
Short interest has climbed sharply and is now doing the talking. At 5.3% of the free float as of May 7 — up 19% on the week and almost 29% over the past month — shorts have been building steadily since late March and accelerated sharply after earnings. That 5.3% level is the highest in the 30-day window, with the bulk of the move concentrated in this week alone. The ORTEX short score has risen to 47.2, up from 42.4 ten days ago, reflecting both the accumulation and the stock's directional move lower. Yet borrow conditions don't signal a squeeze — cost to borrow is a modest 0.48% and availability remains comfortably above distress territory, meaning new shorts face no meaningful friction in adding positions.
Options traders have also grown more defensive, but the shift is measured rather than extreme. The put/call ratio moved to 0.42 on May 8, above its 20-day average of 0.33, with a z-score of 1.56 — elevated but not at the kind of two-standard-deviation reading that would signal panic hedging. The 52-week PCR high for VNT is 1.23, so there's still considerable room for options positioning to tighten further. What's notable is that on May 7 itself — the day of the earnings release — the PCR spiked to 0.53, its highest reading of the month, before pulling back. The options market flagged the event and then partially relaxed, which tells a more ambiguous story than the price action alone.
The Street took a swift axe to price targets the day after earnings. Citigroup, Barclays and Keybanc all maintained positive ratings but cut targets by $10 each — Citi to $44, Barclays to $45, Keybanc to $40. All three still hold constructive views, and the consensus mean target now sits at $43.04, implying roughly 43% upside from the current price. That gap is unusually wide and reflects how fast the stock has repriced rather than a sudden outbreak of bullishness. The EV/EBITDA multiple compressed by 0.78x over the past month to 8.0x, and the P/E has contracted by 1.8 turns to 8.6x — not egregiously cheap, but no longer the premium it was. The 14-day RSI has dropped to 23.8, firmly into oversold territory, though that alone tells you nothing about timing.
The earnings reaction itself was severe. The Q1 print on May 7 drove a single-day decline of 14.1% — the history data shows this reading attached to multiple timestamps around that date. The prior print in April produced a flat-to-positive 1-day move of 1.3%, though that was followed by an 11.7% fall over the ensuing five days. So while Thursday's reaction was extreme, the pattern of post-earnings weakness over a slightly longer window has precedent. The next catalyst is already visible on the calendar: Q1 2026 earnings call follow-up on June 4.
Insider activity adds a cautionary footnote, though the data is now dated. Between mid-February and early March, the CEO, CFO, COO, and Chief Accounting Officer all sold shares at prices around $40-$41 — close to 25-35% above where the stock trades now. Net insider selling over the 90-day period logged totalled roughly 72,600 shares for approximately $2.99 million. None of that is unusual for executives trimming after vesting, but the timing, ahead of what turned into a sharp decline, is a detail worth noting.
Peer behaviour this week underscores how idiosyncratic VNT's move was. Close correlated names KN and CTS gained 11.5% and 8.3% respectively over the same period, while ZBRA and BDC were roughly flat. The divergence is stark. VNT moved entirely on its own earnings story while the broader electronic equipment group recovered ground. Whether shorts are right that the post-print level reflects genuine deterioration, or whether the 43% gap to analyst consensus closes meaningfully, hinges on what the company says on June 4.
See the live data behind this article on ORTEX.
Open VNT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
